In addition, our results in melanoma and colon adenocarcinoma mouse models together with patient survival data suggest that this treatment modality would not be restricted solely to ovarian cancer patients, but rather depletion of FRβ+ TAMs may have clinical impact in patients suffering from other types of solid tumor. This evidence concerns the gene FOLR2 and ovarian cancer.